XNCR

Xencor, Inc. (XNCR) Q2 2024 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2024. Xencor, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics (XmAb) for cancer and serious diseases. The company generates revenue primarily through licensing agreements, milestone payments, and royalties from partners rather than product sales.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenue decreased 63% year-over-year for the quarter and 54% year-over-year for the six months. This is primarily due to the absence of research collaboration revenue from the Janssen (J&J) agreement, which concluded in late 2023, and lower milestone revenue compared to the prior year.
• Increased Net Loss: Net loss widened significantly due to lower revenues and a $20.4 million impairment charge recorded in Q2 2024 related to the company's equity investment in Zenas BioPharma, Inc.
• Investment Losses: The company recorded net losses of $12.0 million (Q2) and $9.7 million (YTD) on equity securities with readily determinable fair values (Astria, INmune, Viridian), compared to gains or smaller losses in the prior year.
• Operating Expenses: R&D expenses remained relatively flat year-over-year ($61.5M vs $60.1M for Q2), while G&A expenses increased by $6.2 million, largely driven by stock-based compensation related to equity award extensions for retired employees.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management expects existing cash, cash equivalents, marketable securities, and potential milestone payments to fund operations into 2027.
• Partnership Updates:
  • J&J: Regained exclusive worldwide rights to plamotamab (CD20 x CD3) in June 2024 after J&J terminated its rights.
  • Genentech: Effective June 1, 2024, Genentech assumed sole responsibility for efbalropendekin alfa; Xencor is now eligible for up to $600 million in milestones and tiered royalties.
  • Alexion: Recognized $6.9 million in non-cash royalty revenue from Ultomiris in Q2 2024.
• Internal Pipeline: The company paused further development of XmAb564 and XmAb662 following Phase 1 studies. It continues to advance vudalimab (Phase 2), XmAb819, XmAb808, and XmAb541 (Phase 1).
• Risks:
  • Material Weakness: The company disclosed a material weakness in internal controls regarding the impairment analysis of equity investments without readily determinable fair values. Remediation efforts are underway.
  • Investment Volatility: Significant exposure to unrealized losses on equity investments in partner companies.
  • Regulatory & Clinical Risk: Success depends on clinical trial outcomes and regulatory approvals for internal and partner candidates.

Investor Verification Checklist

• Verify the sustainability of the $20.4 million impairment charge on Zenas equity and its impact on future valuation models.
• Confirm the timeline and probability of revenue recognition from the Genentech milestone agreement (up to $600M potential).
• Review the progress of the plamotamab program now that Xencor has regained exclusive rights and the associated capital requirements.
• Monitor the remediation status of the material weakness in internal controls over financial reporting.
• Assess the burn rate relative to the 2027 liquidity runway given the current cash usage of ~$120M per six months from operations.